Edition:
India

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

2.70USD
6 Dec 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.70
Open
$2.65
Day's High
$2.75
Day's Low
$2.63
Volume
5,103
Avg. Vol
2,898
52-wk High
$4.75
52-wk Low
$2.52

Latest Key Developments (Source: Significant Developments)

Apollo Endosurgery Files Prospectus Relates To Proposed Resale From Time To Time Of Up To 8 Mln Shares Of Common Stock By Selling Stockholders
Saturday, 24 Aug 2019 

Aug 23 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY INC FILES PROSPECTUS RELATES TO PROPOSED RESALE FROM TIME TO TIME OF UP TO 8 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS.  Full Article

Apollo Endosurgery Says Chairman Informed Of Decision Not To Stand For Re-Election
Friday, 5 Apr 2019 

April 4 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY - ON MARCH 29, RICHARD MEELIA, CHAIRMAN CO INFORMED OF DECISION NOT TO STAND FOR RE-ELECTION AT 2019 ANNUAL MEETING.  Full Article

Apollo Endosurgery Inc Reports Q4 Loss Per Share Of $0.84
Monday, 18 Mar 2019 

March 18 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.APOLLO ENDOSURGERY INC - NET LOSS FOR Q4 2018 WAS $18.4 MILLION COMPARED TO $7.3 MILLION FOR Q4 2017.APOLLO ENDOSURGERY INC - CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $25.0 MILLION AS OF DECEMBER 31, 2018..APOLLO ENDOSURGERY INC - QTRLY LOSS PER SHARE $0.84.APOLLO ENDOSURGERY INC - QTRLY REVENUE $15.2 MILLION VERSUS $16.1 MILLION.  Full Article

Apollo Endosurgery Reports Q3 Loss Per Share Of $0.45
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY, INC. REPORTS THIRD QUARTER 2018 RESULTS.Q3 REVENUE $14.1 MILLION VERSUS I/B/E/S VIEW $16.2 MILLION.QTRLY LOSS PER SHARE $0.45.Q3 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.APOLLO ENDOSURGERY - CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $29.5 MILLION AS OF SEPT 30, 2018.  Full Article

Apollo Endosurgery Inc - QTRLY Net Loss Per Share, Basic And Diluted $0.53
Thursday, 9 Aug 2018 

Apollo Endosurgery Inc ::APOLLO ENDOSURGERY, INC. REPORTS SECOND QUARTER 2018 RESULTS.Q2 REVENUE $15.8 MILLION VERSUS I/B/E/S VIEW $16.6 MILLION.CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $35.4 MILLION AS OF JUNE 30, 2018.QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.53.Q2 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.  Full Article

Apollo Endosurgery Announces Pricing Of $20.6 Million Public Offering Of Common Stock
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY, INC. ANNOUNCES PRICING OF $20.6 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.75 MILLION COMMON SHARES PRICED AT $5.50PER SHARE.  Full Article

Apollo Endosurgery Announces Approval Orbera365 In Saudi Arabia
Tuesday, 24 Apr 2018 

April 23 (Reuters) - Apollo Endosurgery Inc ::APOLLO ENDOSURGERY ANNOUNCES APPROVAL OF THE NEW 12-MONTH WEIGHT LOSS BALLOON - ORBERA365™ - IN THE KINGDOM OF SAUDI ARABIA.APOLLO ENDOSURGERY INC - SAUDI FOOD AND DRUG AUTHORITY APPROVED ORBERA365 MANAGED WEIGHT LOSS SYSTEM & ISSUED MEDICAL DEVICE MARKETING AUTHORIZATION.APOLLO ENDOSURGERY INC - MDMA ALLOWS CO TO MARKET ORBERA365 IN KINGDOM OF SAUDI ARABIA WITH ITS EXCLUSIVE DISTRIBUTION PARTNER, AL-NOZHA MEDICAL.  Full Article